These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 498662)

  • 1. [Plasminogen concentration in the cerebrospinal fluid of patients with various neurological diseases (author's transl)].
    Maruyama I; Igata A
    Rinsho Shinkeigaku; 1979 Aug; 19(8):481-5. PubMed ID: 498662
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fibrinogen degradation products in the cerebrospinal fluid in central nervous system diseases].
    Kolanowska H; Solecka B
    Pol Przegl Chir; 1980 Aug; 52(8):729-34. PubMed ID: 7433284
    [No Abstract]   [Full Text] [Related]  

  • 3. [Significance of fibrin fibrinogen degradation products in the cerebrospinal fluid in the neonatal period].
    Dalens B; Bezou MJ; Coulet M; Raynaud EJ
    Ann Pediatr (Paris); 1983 Jan; 30(1):59-62. PubMed ID: 6830109
    [No Abstract]   [Full Text] [Related]  

  • 4. Coagulation and fibrinolytic activity of cerebrospinal fluid.
    Anderson M; Matthews KB; Stuart J
    J Clin Pathol; 1978 May; 31(5):488-92. PubMed ID: 649775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro studies to elucidate the fibrinolytic activity in cerebrospinal fluid altered by inflammation and hemorrhage and having pathologic protein values].
    Hindersin P; Heidrich R
    Psychiatr Neurol Med Psychol (Leipz); 1977 Aug; 29(8):465-73. PubMed ID: 144927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fibrinogen degradation products in human CSF: a preliminary clinical study].
    Li YP
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1986 Jun; 19(3):142-5. PubMed ID: 3757627
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrin-fibrinogen degradation products in cerebrospinal fluid.
    Brueton MJ; Breeze GR; Stuart J
    J Clin Pathol; 1976 Apr; 29(4):341-4. PubMed ID: 932226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cerebrospinal fluid plasminogen assay in different neurological diseases (author's transl)].
    Aznar JA; Vilches JJ; Mayans JR; Tascón A; Monsalvez F; Marty ML
    Sangre (Barc); 1976; 21(2):225-8. PubMed ID: 948774
    [No Abstract]   [Full Text] [Related]  

  • 9. Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
    Li F; Zhang G; Zhao W
    Chin Med J (Engl); 2003 Mar; 116(3):475-7. PubMed ID: 12781064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunological diagnostics of cerebrospinal fluid in aging processes of the brain (author's transl)].
    Böning J
    Nervenarzt; 1979 Apr; 50(4):237-40. PubMed ID: 460503
    [No Abstract]   [Full Text] [Related]  

  • 11. [Fibrin-fibrinogen degradation products in cerebrospinal fluid of patients with meningococcal infections (author's transl)].
    Bajo R; Vaca R; Elduayen R; Zarallo L; Cardesa JJ; Pérez-Miranda M
    Med Clin (Barc); 1980 Nov; 75(8):338-41. PubMed ID: 7442335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Penetration of 99mTcO4- into cerebrospinal fluid from blood on brain scintigraphy (author's transl)].
    Takeyama E; Ookubo T; Baba M; Beppu T; Kitamura K
    No Shinkei Geka; 1975 May; 3(5):389-97. PubMed ID: 1239680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Penetration of cephaloridine and cephalothin into the cerebrospinal fluid-clinical study (author's transl)].
    Kano M; Ohta H; Kinjo T; Ito A
    No Shinkei Geka; 1975 Apr; 3(4):305-12. PubMed ID: 1239674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Signification of fibrinogen degradation (FDP) product in CSF during the neonatal period (author's transl)].
    Dalens B; Bezou MJ; Coulet M; Raynaud EJ
    Pathol Biol (Paris); 1981 Dec; 29(10):605-8. PubMed ID: 7041056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fibrin(ogen degradation product concentration (SFP) as a diagnostic parameter for the differentiation of artifical and essential blood in cerebrospinal fluid].
    Hindersin P; Heidrich R
    Psychiatr Neurol Med Psychol (Leipz); 1978 Jan; 30(1):36-9. PubMed ID: 643973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
    Collatos C; Barton MH; Prasse KW; Moore JN
    J Am Vet Med Assoc; 1995 Aug; 207(4):465-70. PubMed ID: 7591947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus.
    Kwieciński J; Kłak M; Trysberg E; Blennow K; Tarkowski A; Jin T
    Arthritis Rheum; 2009 Jul; 60(7):2094-101. PubMed ID: 19565516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibrinogen degradation products in the cerebrospinal fluid of children with lymphoblastic leukemia].
    Borkowski W; Kolanowska H; Depowska T; Kaczor Z
    Pediatr Pol; 1981 Sep; 56(9):1017-20. PubMed ID: 6948264
    [No Abstract]   [Full Text] [Related]  

  • 19. [A preliminary study of concentration of cyclic AMP in the cerebrospinal fluid of neurosurgical patients (author's transl)].
    Du ZW
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1982 Feb; 15(1):30-2. PubMed ID: 6284454
    [No Abstract]   [Full Text] [Related]  

  • 20. [Proteinase inhibitors and fibrinogen split products in patients with malignant diseases (author's transl)].
    Schwarz HP; Aiginger P; Kuzmits R
    Acta Med Austriaca; 1981; 8(1):22-5. PubMed ID: 6165218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.